CD155

Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)

Retrieved on: 
Thursday, December 7, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Data, Arm, Trae tha Truth, CD112, Safety, NYSE, Cancer, Ligand, Progression-free survival, Incidence, Merck & Co., ESMO, Patient, PFS, Weakness, DOR, Pembrolizumab, Neutropenia, Lung cancer, ORR, Melanoma, CD155, Diarrhea, Anemia, TIGIT, Immunotherapy, Neoplasm, OS, Docetaxel, MRK, NSCLC, Pharmaceutical industry, Vaccine, Merck

Vibostolimab/pembrolizumab alone did not show an improvement in median PFS compared to docetaxel alone (2.7 months vs. 3.2 months; HR=1.40 [95% CI, 0.96-2.02]; p=0.9622).

Key Points: 
  • Vibostolimab/pembrolizumab alone did not show an improvement in median PFS compared to docetaxel alone (2.7 months vs. 3.2 months; HR=1.40 [95% CI, 0.96-2.02]; p=0.9622).
  • Vibostolimab/pembrolizumab plus docetaxel improved OS compared with docetaxel alone, though these results did not reach statistical significance (HR=0.76 [95% CI, 0.50-1.15]).
  • The safety profile of vibostolimab/pembrolizumab was consistent with that observed for vibostolimab and pembrolizumab in previously reported studies, with no new safety signals observed.
  • Ongoing Phase 3 studies in lung cancer include KeyVibe-003 , KeyVibe-006 , KeyVibe-007 and KeyVibe-008 , as well as KeyVibe-010 in melanoma.

Over 40 Anti TIGIT Antibodies in Clinical Trials: Unveiling the Promising Landscape of Immune Checkpoint Modulation - ResearchAndMarkets.com

Retrieved on: 
Friday, September 8, 2023
Infectious Diseases, Health, Clinical Trials, Yale University, Plastic, Construction, Electronics, ITIM, Infection, Ligand, Roche, University, NK, Compugen, Bristol Myers Squibb, AstraZeneca, CD155, Cancer, Drug discovery, TIGIT, CD112, MD Anderson Cancer Center, Nanotechnology, CD113, Vaccine, Pharmaceutical industry, Oil, BeiGene

The report provides insights into the clinical trials and market dynamics of anti TIGIT antibodies.

Key Points: 
  • The report provides insights into the clinical trials and market dynamics of anti TIGIT antibodies.
  • TIGIT (T cell immunoreceptor with Ig and ITIM domains) is an immune checkpoint protein that has gained attention as a potential therapeutic target.
  • Over 40 anti TIGIT antibodies are being evaluated in clinical trials.
  • TIGIT inhibitors are being investigated in preclinical and clinical studies, aiming to replicate the success of immune checkpoint inhibitors in various cancers.

IMIDomics Inc. Secures Exclusive Worldwide Licensing Agreement with TNAX Biopharma Corporation for TNAX101A (IMB1001), A Promising Drug Candidate for Immune-Mediated Inflammatory Diseases

Retrieved on: 
Wednesday, September 6, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Human, IMID, Hope, Multimedia, Immunotherapy, Animal, CD155, MD, Patient, CD226, Cytokine, Immune-mediated inflammatory diseases, Pharmaceutical industry

IMIDomics Inc., a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), today announced an exclusive license agreement with TNAX Biopharma Corporation (TNAX), an innovator in biotechnology.

Key Points: 
  • IMIDomics Inc., a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), today announced an exclusive license agreement with TNAX Biopharma Corporation (TNAX), an innovator in biotechnology.
  • Under this agreement, TNAX is granting IMIDomics the worldwide rights to develop, manufacture, commercialize and sublicense IMB1001, a highly promising humanized antibody targeting CD226, a breakthrough target with the potential to treat IMIDs.
  • This identification of CD226 and the subsequent licensing of IMB1001, a promising preclinical drug candidate, validates IMIDomics’ approach to accelerating the development of treatments for these complex conditions.
  • “We are delighted to partner with TNAX to further advance the development of IMB1001,” said H. Daniel Perez, MD, Chief Development Officer of IMIDomics.

Istari Oncology Announces First Patient Dosed in the Non-Muscle-Invasive Bladder Cancer (NMIBC) Substudy of the LUMINOS-103 Basket Trial Evaluating Lerapolturev Monotherapy

Retrieved on: 
Tuesday, January 31, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, APC, TURBT, Immunotherapy, Cystectomy, CD155, Patient, Risk, NMIBC, TIS, Carcinoma, BCG, MS, Pharmaceutical industry, Medical imaging, MD

Istari Oncology, Inc. , a clinical-stage biotechnology company focused on development of the novel immune activator lerapolturev for the treatment of solid tumors, today announced the first patient has been dosed via intravesicular instillation in the non-muscle-invasive bladder cancer (NMIBC) cohort of the LUMINOS-103 basket trial.

Key Points: 
  • Istari Oncology, Inc. , a clinical-stage biotechnology company focused on development of the novel immune activator lerapolturev for the treatment of solid tumors, today announced the first patient has been dosed via intravesicular instillation in the non-muscle-invasive bladder cancer (NMIBC) cohort of the LUMINOS-103 basket trial.
  • LUMINOS-103 is a dynamic phase 1/2 open-label basket trial evaluating the administration of lerapolturev with or without PD-1/L1 inhibitors in adult subjects with solid cancers.
  • If successful, the planned patient population for phase 2 will be patients with low- to intermediate-risk BCG-naïve disease.
  • “We’re pleased to be the exclusive site for the NMIBC sub-study,” said Dr. Neal Shore principal investigator and Director, Carolina Urologic Research Center.

23andMe Announces Extension of GSK Collaboration and Update on Joint Immuno-oncology Program

Retrieved on: 
Tuesday, January 18, 2022
Medicine, Securities Exchange Act of 1934, Research, GlaxoSmithKline, Patient, Mace Head Atmospheric Research Station, Vii, Drug discovery, 23andMe, Publication, NK, Antibody, SEC, Regulation of tobacco by the U.S. Food and Drug Administration, Probability, COVID-19, Genome, Database, CA, Lijun International Pharmaceutical (Holding) Co. Ltd., Phase 1, Degenerative disease, GLOBE, U.S. Securities and Exchange Commission, GSK, SVP, CD155, Marketing, Therapy, Program, CD226, Genetics, Drug development, Consumer, Cancer, Immune system, Food, FDA, Security (finance), Drug Quality and Security Act, CD96, Coronavirus, Securities Act of 1933, Terminology, Pharmaceutical industry, EU

SUNNYVALE, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and therapeutics company, today provided an update on its collaboration with GlaxoSmithKline plc (“GSK”). GSK has elected to exercise its option to extend the exclusive target discovery period of the ongoing collaboration with 23andMe for an additional year to July 2023. 23andMe will receive a one-time payment of $50 million to extend the period. In addition, 23andMe has elected to take a royalty option on its joint immuno-oncology antibody collaboration program with GSK targeting CD96 (GSK6097608, a.k.a. GSK’608), currently in Phase 1 studies. GSK will be solely responsible for GSK’608’s subsequent development in later-stage clinical trials, including full development costs moving forward.

Key Points: 
  • GSK has elected to exercise its option to extend the exclusive target discovery period of the ongoing collaboration with 23andMe for an additional year to July 2023.
  • In addition, 23andMe has elected to take a royalty option on its joint immuno-oncology antibody collaboration program with GSK targeting CD96 (GSK6097608, a.k.a.
  • Our collaboration with 23andMe continues to exceed expectations, with more than 40 genetically validated drug discovery programs in the GSK portfolio that were initiated under the collaboration, said John Lepore, SVP and Head of Research at GSK.
  • This allows 23andMe to invest further in its advancing pipeline of therapeutic programs, largely identified under the GSK collaboration.

Taiho Pharmaceutical Exercises Option for an Exclusive License to Arcus Biosciences’ Anti-TIGIT Program in Japan and Certain Territories in Asia

Retrieved on: 
Tuesday, November 30, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Patient, Private Securities Litigation Reform Act, Cancer, Durvalumab, Taiho Pharmaceutical, Achievement, Biology, NYSE, Exercise, Large-cell lung carcinoma, Partnership, Health, CD226, SEC, Urology, NK, AstraZeneca, Program, CD73, COVID-19, Physician, TIGIT, Twitter, List of life sciences, Allergy, PD-1, PHASE 2, CD155, Quality of life, Pharmaceutical industry, Vaccine, AB308, Zimberelimab, Taiho Pharmaceutical, Arcus Biosciences, AB308, ZIMBERELIMAB, TAIHO PHARMACEUTICAL, ARCUS BIOSCIENCES

This option exercise is based on an option and license agreement between Taiho and Arcus contracted in September 2017.

Key Points: 
  • This option exercise is based on an option and license agreement between Taiho and Arcus contracted in September 2017.
  • Taiho has already obtained exclusive rights to etrumadenant (AB928), an adenosine A2a/A2b receptor antagonist, and zimberelimab (AB122), an anti-PD-1 monoclonal antibody.
  • In Japan, Taiho is conducting a Phase 1 platform trial for zimberelimab in combination with other Taiho products.
  • Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.

Istari Oncology Presents Data on Its PVSRIPO Immunotherapy at the Annual November Meetings for the Society for Immunology of Cancer (SITC) and the Society for Neuro-Oncology (SNO)

Retrieved on: 
Tuesday, November 9, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Safety, SITC, Research Triangle Park, SNO, Wizards (Middle-earth), Mary K. Estes, EST, Food, Society, Immunotherapy, Tumor microenvironment, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PVSRIPO, Cancer, Neoplasm, APC, CD155, B cell, Patent, Cell, Glioblastoma, Pharmaceutical industry, Vaccine, Communications satellite

PVSRIPO is an investigational immunotherapy based on the liveattenuated Sabin type 1 poliovirus vaccine that has been genetically modified for safety.

Key Points: 
  • PVSRIPO is an investigational immunotherapy based on the liveattenuated Sabin type 1 poliovirus vaccine that has been genetically modified for safety.
  • PVSRIPO has been shown to activate a patients innate and adaptive immune system to facilitate a systemic anti-tumor immune response.
  • Because PVSRIPO utilizes CD155 (the poliovirus receptor) to enter both solid tumor cells and antigenpresenting cells (APCs) in the tumor microenvironment, PVSRIPO has the potential to treat a variety of cancers.
  • PVSRIPO is an investigational immunotherapy based on the live-attenuated Sabin type 1 poliovirus vaccine that has been genetically modified for safety.

Istari Oncology Enters Into Manufacturing Agreement With FUJIFILM Diosynth Biotechnologies to Advance its Viral Immunotherapy PVSRIPO

Retrieved on: 
Tuesday, October 26, 2021
Safety, Fujifilm, Head, Melanoma, Biotechnology, CDMO, Research Triangle Park, Sabin, Vaccine, Knowledge, FDB, Contract, A-DNA, Partnership, Patient, CGMP, FDA, Food, Immortalised cell line, Mitsubishi, PVSRIPO, CD155, RTP, Diosynth, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Glioblastoma, Patent, Mitsubishi Corporation, Solution, APC, GLOBE, Tumor microenvironment, Bladder cancer, Pharmaceutical industry

FUJIFILM Diosynth Biotechnologies is a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and viral gene therapies.

Key Points: 
  • FUJIFILM Diosynth Biotechnologies is a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and viral gene therapies.
  • Istari Oncology selected FUJIFILM Diosynth Biotechnologies as its partner for drug substance manufacturing and filling of its recombinant viral immunotherapy PVSRIPO, which is based on the Sabin Type 1 poliovirus vaccine.
  • Drug substance manufacturing and filling will be carried out in FUJIFILM Diosynth Biotechnologies state-of-the-art cGMP manufacturing facility in College Station, Texas.
  • Our decision to collaborate with FUJIFILM Diosynth Biotechnologies on the manufacturing of PVSRIPO has already paid off in multiple ways, said Jamie Iudica, chief manufacturing officer, Istari Oncology.

First Patient Dosed With PVSRIPO in Istari Oncology’s LUMINOS-103 Phase 1/2 Bladder Cancer Sub-Study

Retrieved on: 
Tuesday, October 12, 2021
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Tumor microenvironment, Neoplasm, Patent, Research Triangle Park, Metastasis, Adult, PVSRIPO, RECIST, Neoadjuvant therapy, Food, Glioblastoma, American Cancer Society, Safety, Melanoma, APC, BCAN, MD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Toxicity, Bladder cancer, Cancer, CD155, CEO, B cell, Patient, Disease, PD-1, Research, Head, Medical imaging, Vaccine, Pharmaceutical industry, Dietary supplement, PVSRIPO, Istari Oncology, PVSRIPO, ISTARI ONCOLOGY

PVSRIPO has been shown to activate a patients innate and adaptive immune system to facilitate a systemic anti-tumor immune response.

Key Points: 
  • PVSRIPO has been shown to activate a patients innate and adaptive immune system to facilitate a systemic anti-tumor immune response.
  • We look forward to further evaluating its therapeutic value as we aim to expand the potential treatment options for patients living with bladder cancer.
  • The phase 2 LUMINOS-103 bladder cancer sub-study will be conducted at approximately 10 research sites across the U.S.
  • Bladder cancer becomes more difficult to treat as it grows through the layers of the bladder and into the muscle wall.

Istari Oncology Initiates Its Phase I/II Sub-Study Evaluating PVSRIPO in Patients with Head and Neck Cancer

Retrieved on: 
Tuesday, August 17, 2021
Biotechnology, Health, Oncology, Clinical Trials, Cancer, CD155, HPV, CD8, Glioblastoma, PD-1, PVSRIPO, MPA, Tobacco, Immunotherapy, Research, Disease, Man, Chimera, Food, Tumor microenvironment, Cell, Multimedia, Poliovirus, Infection, HNSCC, Rehabilitation, Safety, Adult, APC, Head, B cell, Patient, Wizards (Middle-earth), Bladder cancer, Neoplasm, Woman, Patent, Research Triangle Park, Regulation of tobacco by the U.S. Food and Drug Administration, Pharmaceutical industry, Vaccine, Medical imaging, PVSRIPO, Istari Oncology, PVSRIPO, ISTARI ONCOLOGY

LUMINOS-103 is a Phase I/II, open-label, multi-center, single-arm basket trial evaluating the administration of PVSRIPO with or without PD-1/L1 inhibitors across multiple tumor types.

Key Points: 
  • LUMINOS-103 is a Phase I/II, open-label, multi-center, single-arm basket trial evaluating the administration of PVSRIPO with or without PD-1/L1 inhibitors across multiple tumor types.
  • The company began the LUMINOS-103 basket trial earlier this year, opening recruitment to patients with bladder cancer in two separate cohorts.
  • We enter this next phase of PVSRIPO development in patients with solid tumors with great enthusiasm as we progress toward further evaluating the impact of PVSRIPO on patients with head and neck squamous cell carcinoma, said Matt Stober, president and chief executive officer at Istari Oncology.
  • For more information about Istari Oncology and its ongoing clinical trials and research on PVSRIPO, visit www.istarioncology.com .